Stock screener

CUE

Conviction 49HealthcareScan · Tue, Sep 8, 2026
Rising three methods
CUE$30.14+9.82%
ResistanceSupportVol 14Insider buyInsider sell
63 bars
9
2
Vol MA14 146.64K
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Cue Biopharma, Inc.PHARMACEUTICAL PREPARATIONSwww.cuebiopharma.com
Price30.14
Change+9.82%
Gap-0.98%
Rel volume0.99×
Avg volume184.04K
Avg $ vol5.12M
SMA 2027.66
SMA 5029.36
SMA 20013.14
Price vs 50+2.63%
Price vs 200+129.36%
MA stackbullish
50/200 cross
Supertrenddown · 33.63
RSI (14)55
MACD hist0.34
MACD crossbull · 7d
Stoch %K / %D99 / 70
ADX (14)12
+DI / −DI21 / 14
RSI divergence
MACD divergence
ATR %+11.12%
ADR %13.02%
52w high36.78
52w low0.1770
From 52w high-18.07%
Above 52w low+16925.42%
New 52w highNo
SqueezeOn · 15d
Bollinger width36.22%
%B0.75
Donchian pos62.89%
Donchian high34.61
Donchian low22.56
AVWAP (52w high)29.01
vs AVWAP high+3.87%
AVWAP (52w low)2.48
vs AVWAP low+1117.44%
OBV trendFlat
Chaikin MF (20)0.10
Today vs 20d0.99×
Avg vol (14d)146.64K
Avg vol (20d)184.04K
Avg $ vol (20d)5.12M
Market cap218.91M
RS 3m (vs SPY)-11.28%
RS 6m (vs SPY)+9038.22%
RS line new highNo
Trend template7/8
Technical rank92.5
1 week+18.08%
1 month+11.12%
3 months+3.63%
6 months+9911.63%
1 year+3763.46%
YTD+8831.54%
P/E-8.23
P/B94.77
P/S7.97
P/FCF-10.01
EPS-0.2800
Div yield
ROE
ROA-86.63%
Debt/Eq1.73
Current1.25
EV/EBITDA-8.03
Gross margin
Net margin-96.85%
Rev growth195.75%
EPS growth34.60%
Price target
Target upside
Analyst rating
Institutional23.67%
Ent. value205.52M
Revenue7.88M
Net income-153.07M
Gross profit
Free cash flow-21.86M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out4.2M
Employees29
ListedTue, Jan 2, 2018
Free float94.71M
Float %97.2%
Short interest327.44K
Days to cover1.6d
Short volume51.3%
Squeeze score16 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeC
Conviction49 / 100
Pattern quality
Tech rank92.5 / 100
Group rank96 / 100 · Leading
Status lane
Setup direction
Pattern family
Resistance
Support
Days since event
Candle confirmRising three methods
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CUE

All disclosures →
No recent disclosed trades by Congress in CUE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CUE · 4 buys · 6 sells

InsiderSideShares
Garzone Pamela
Director · Common Stock · 2026-07-09
Grant18.9K
Sarraf Pasha
Director · Common Stock · 2026-07-09
Grant18.4K
Meluzio Michael Vincent
VP, Prin. Accounting Officer · Common Stock · 2026-08-13
Exercise13.65K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Exercise18.2K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Sell2.38K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Sell6.44K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Sell4
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Exercise18.2K
Meluzio Michael Vincent
VP, Prin. Accounting Officer · Common Stock · 2026-08-13
Sell1.52K
Meluzio Michael Vincent
VP, Prin. Accounting Officer · Common Stock · 2026-08-13
Sell4.11K

SEC filings

EDGAR filings in CUE · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.